Status:
UNKNOWN
Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Retinitis Pigmentosa
Eligibility:
All Genders
18-40 years
Phase:
PHASE2
Brief Summary
Retinitis pigmentosa (RP) is an inherited retinal disease with great heterogeneity. RP comprises a large group of genetic disorders causing progressive loss of vision. Despite many suggested treatment...
Eligibility Criteria
Inclusion
- RP patients with the best-corrected visual acuity (BCVA) between 20/30 and 20/120.
Exclusion
- Patients with other types of retinal dystrophy
- Systemic or syndromic RP
- RP patients with cystoid macular edema (CME) and the presence of cystoid changes in the foveal area
- RP patients with other concomitant ocular diseases
- RP patients with a history of any ocular surgery or intravitreal injection within 6 months before the study enrollment
- RP patients who have received any supplemental drugs during the past three months before the study enrollment
Key Trial Info
Start Date :
April 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 20 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04864496
Start Date
April 17 2021
End Date
December 20 2022
Last Update
April 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ophthalmic Research Center
Tehran, Iran